| Code | CSB-RA004936MB20HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Selicrelumab, targeting CD40, a critical costimulatory receptor belonging to the tumor necrosis factor receptor superfamily. CD40 is primarily expressed on antigen-presenting cells, including B cells, dendritic cells, and macrophages, where it plays a pivotal role in adaptive immunity by facilitating T cell activation and promoting immune responses. The CD40-CD40L signaling pathway is implicated in various pathological conditions, including autoimmune diseases, inflammatory disorders, and cancer, making it an important therapeutic target for immune modulation and cancer immunotherapy research.
Selicrelumab is an investigational agonistic antibody that has been evaluated in clinical studies for its potential to enhance anti-tumor immunity by activating antigen-presenting cells and promoting T cell-mediated responses. This biosimilar provides researchers with a valuable tool for investigating CD40-mediated immune activation mechanisms, exploring combination immunotherapy strategies, and studying the role of costimulatory pathways in tumor microenvironments and immune-related diseases.
There are currently no reviews for this product.